肿瘤细胞治疗研究
英文原题：Differential diagnosis and identification of prognostic markers for peripheral T-cell lymphoma subtypes based on flow cytometry immunophenotype profiles.
PB替代BM监测PTCLs肿瘤负荷或MRD的灵敏度高达85.71%，可缓解临床采样的巨大压力，提高患者依从性。
我们比较了15个标志物在PTCL（外周T细胞淋巴瘤）亚型和T-CUS（意义未明的T细胞克隆）中的差异表达，并总结了各亚型的特异性免疫表型特征及其对预后的影响。PD-1和CD10是AITL（血管免疫母细胞性T细胞淋巴瘤）的诊断标志物。为避免与良性克隆的T-CUS混淆，建议将AITL定义为以PD-1+%>38.01和/或CD10+%>7.46为界。T细胞来源的ENKTL-N（结外NK/T细胞淋巴瘤）特异性表达CD56。ALCL（间变性大细胞淋巴瘤）特征性表达CD30和HLA-DR。PTCL-NOS（非特指型外周T细胞淋巴瘤）仍缺乏相对特异的表型，且容易丢失基本谱系标志物CD3、CD5和CD7。T-CUS的判定可通过骨髓整体评估和一定时间的随访来验证。聚类结果显示，8个特定标志物在5组间的表达存在显著差异，提示在PTCLs亚型鉴定中可分析相关标志物的组合。本研究探讨了TRBC1联合CD45RA/CD45RO在检测T细胞克隆性方面的优势，能够高效、灵敏地同时分析多个目标T细胞群体。PB替代BM监测PTCLs肿瘤负荷或MRD（微小残留病）的灵敏度高达85.71%，可缓解临床采样的巨大压力并提高患者依从性。CD7、CD38和Ki-67是AITL的预后指标。PTCL-NOS上的CD3和CD8，以及ENKTL-N上的CD56和HLA-DR具有预后作用。本研究支持并验证了当前PTCL亚型的分类，并建立了可用于精准诊断的免疫表型谱。强调了PTCL免疫表型在常规分类诊断、克隆性确认、预后预测和治疗靶点选择中的重要临床价值。
We compared the differential expression of 15 markers in PTCL (Peripheral T-cell lymphoma) subtypes and T-CUS (T-cell clones of uncertain significance), and summarized the specific immunophenotype profiles of each subtype and its impact on prognosis. PD-1 and CD10 are diagnostic markers for AITL (angioimmunoblastic T-cell lymphoma). To avoid confusion with T-CUS of benign clones, it is recommended to define AITL as bounded by PD-1+%>38.01 and/or CD10+%>7.46. T cell-derived ENKTL-N (extranodal NKT cell lymphoma) specifically expresses CD56. ALCL (anaplastic large cell lymphoma) characteristically expresses CD30 and HLA-DR. PTCL-NOS (peripheral T-cell lymphoma unspecified) still lacks a relatively specific phenotype and is prone to loss of basic lineage markers CD3, CD5, and CD7. The determination of T-CUS can be verified by the overall assessment of the bone marrow and a certain period of follow-up. The clustering results showed that the expression of 8 specific markers was significantly different among the 5 groups, suggesting that a combination of related markers can be analyzed in the identification of PTCLs subtypes. The study explores the advantages of TRBC1 combined with CD45RA/CD45RO in detecting T cell clonality, which can efficiently and sensitively analyze multiple target T cell populations at the same time. The sensitivity of PB to replace BM to monitor the tumor burden or MRD (minimal residual disease) of PTCLs is as high as 85.71%, which can relieve the huge pressure of clinical sampling and improve patient compliance. CD7, CD38, and Ki-67 are prognostic indicators for AITL. CD3 and CD8 on PTCL-NOS, and CD56 and HLA-DR on ENKTL-N have prognostic role. This study supports and validates the current classification of PTCL subtypes and establishes an immunophenotypic profile that can be used for precise diagnosis. The important clinical value of PTCLs immunophenotype in routine classification diagnosis, clonality confirmation, prognosis prediction, and treatment target selection was emphasized.
MEMBER ACCOUNT
登录成功会直接打开下一页。
